secwatch.observer — SEC 8-K summary
======================================

Issuer:     FRACTYL HEALTH, INC. (GUTS)
CIK:        0001572616
Form:       8-K
Filed at:   2024-06-24T23:59:59+00:00
Accession:  0000950170-24-076424
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fractyl Health accelerates REMAIN-1 study, expands REVITALIZE-1 eligibility
---------------------------------------------------------------------------

- REMAIN-1 weight maintenance study accelerated; open-label REVEAL-1 data expected Q4 2024.
- Midpoint data analysis for REMAIN-1 now anticipated in Q2 2025.
- FDA approved protocol amendment for REVITALIZE-1: expands eligibility to any glucose lowering agent; potential U.S. treatment population ~6x to ~25M patients.
- Topline data from REVITALIZE-1 expected mid-2025.
- Preclinical data for Rejuva gene therapy vs semaglutide showed greater, more durable weight loss in mice; presented at ADA 84th Scientific Sessions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1572616/000095017024076424/0000950170-24-076424-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1572616/000095017024076424/guts-20240624.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-076424

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer